Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
05.11
2023
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
05.10
2023
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
05.05
2023
Addex Convenes Annual General Meeting 2023
05.04
2023
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
04.05
2023
Addex Completes $5.0 Million Equity Financing
04.04
2023
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
04.03
2023
Addex Raises $5.0 Million in Equity Financing
03.30
2023
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
03.28
2023
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
03.16
2023
Addex Announces Upcoming Conferences it will participate for H1 2023
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back